A Phase II Evaluation of Aflibercept in the Treatment of Recurrent or Persistent Endometrial Cancer: a Gynecologic Oncology Group study

PURPOSE: Aflibercept targets vascular endothelial growth factor and placental growth factor. We evaluated activity and toxicity of aflibercept in recurrent/persistent endometrial cancer patients. Biomarkers and association with clinical characteristics and outcome were explored. METHODS: Eligible pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Coleman, Robert L., Sill, Michael W., Lankes, Heather A., Fader, Amanda Nickles, Finkler, Neil J., Hoffman, James S., Rose, Peter G., Sutton, Gregory P., Drescher, Charles W., McMeekin, D. Scott, Hu, Wei, Deavers, Michael, Godwin, Andrew K., Alpaugh, R. Katherine, Sood, Anil K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3568489/
https://ncbi.nlm.nih.gov/pubmed/22922531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.08.020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados